This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB02383/identifier/chemspider/
n16http://linked.opendata.cz/resource/drugbank/drug/DB02383/identifier/chebi/
n6http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB02383/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB02383/identifier/kegg-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB02383/identifier/pdb/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB02383/identifier/bindingdb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB02383/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB02383/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/property/
n12http://linked.opendata.cz/resource/drugbank/drug/DB02383/identifier/kegg-drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB02383/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB02383
rdf:type
n3:Drug
n3:description
Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. It was sold under the tradename Alredase. [Wikipedia]
n3:generalReferences
# Sestanj K, Bellini F, Fung S, Abraham N, Treasurywala A, Humber L, Simard-Duquesne N, Dvornik D: N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. J Med Chem. 1984 Mar;27(3):255-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6422042 # Kador PF, Kinoshita JH, Sharpless NE: Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J Med Chem. 1985 Jul;28(7):841-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3925146
n3:group
withdrawn
n3:indication
For the pharmacological control of certain diabetic complications.
owl:sameAs
n6:DB02383 n19:DB02383
dcterms:title
Tolrestat
adms:identifier
n8:46508274 n9:TOL n10:53359 n11:C01621 n12:D02323 n13:48194 n14:DB02383 n15:16314 n16:48549 n17:Tolrestat
n3:toxicity
Oral, mouse: LD50 = 300 mg/kg; Oral, rabbit: LD50 = 3200 mg/kg; Oral, rat: LD50 = 980 mg/kg.
n3:IUPAC-Name
n4:271B58B7-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B58BD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B58BC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B58B9-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B58BA-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B58BB-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B58B5-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B58B3-363D-11E5-9242-09173F13E4C5 n4:271B58B6-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B58B4-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B58C3-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B58C4-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B58BE-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B58BF-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B58C1-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B58C0-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B58C2-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
82964-04-3
n3:Bioavailability
n4:271B58C9-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B58CB-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B58CC-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B58C8-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B58C7-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B58CA-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B58B8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B58C5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B58C6-363D-11E5-9242-09173F13E4C5